| Myasthenia Gravis, Generalized
Soliris vs Uplinza
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Soliris vs Uplizna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUplizna has a higher rate of injection site reactions vs Soliris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uplizna but not Soliris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Soliris
Uplizna
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
IV infusion
Every 6 months
CD19-directed cytolytic antibody
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Neuromyelitis Optica
- Immunoglobulin G4-Related Disease
- Myasthenia Gravis, Generalized
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Neuromyelitis Optica, Immunoglobulin G4-Related Disease, Myasthenia Gravis, Generalized Initial dose: 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion; subsequent doses: 300 mg IV infusion every 6 months starting 6 months from first infusion; premedicate with a corticosteroid (methylprednisolone 80-125 mg IV), antihistamine (diphenhydramine 25-50 mg oral), and antipyretic (acetaminophen 500-650 mg oral) before each infusion; dilute in 250 mL 0.9% Sodium Chloride and infuse over approximately 90 minutes.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- History of life-threatening infusion reaction to inebilizumab-cdon or any excipient
- Active hepatitis B infection (confirmed by positive HBsAg and anti-HBV tests)
- Active or untreated latent tuberculosis
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Most common (>=10%) Urinary tract infection, nasopharyngitis, infusion-related reaction, arthralgia, headache, lymphopenia
Serious Infusion reactions, infections, reduction in immunoglobulins
Pharmacology
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
CD19-directed humanized afucosylated IgG1 monoclonal antibody; binds CD19 on pre-B and mature B lymphocytes and induces antibody-dependent cellular cytolysis, depleting B-cell counts within 8 days of infusion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Soliris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Uplizna
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Soliris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uplizna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Soliris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Uplizna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Soliris.
$0
Amgen By Your Side Copay Assistance Program: UpliznaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SolirisView full Soliris profile
UpliznaView full Uplizna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.